Paolo Fundaro - 27 May 2021 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.

Role
Director, 10%+ Owner
Signature
/s/ Mary J. Grendell, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
27 May 2021
Net transactions value
$0
Form type
4
Filing time
01 Jun 2021, 19:01:54 UTC
Next filing
27 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICPT Common Stock Award $0 +7,029 +33% $0.000000 28,057 27 May 2021 Direct F1
holding ICPT Common Stock 4,000,000 27 May 2021 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICPT Option to Purchase Common Stock Award $0 +12,089 $0.000000 12,089 27 May 2021 Common Stock 12,089 $17.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders.
F2 These shares are held by Genextra S.p.A. ("Genextra"). Mr. Fundaro is the Chief Executive Officer of Genextra. He disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.
F3 All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney